August 30, 2017 (HealthDay News) Kymriah approved for patients up to 25 years of age with refractory or relapsed B-cell precursor ALL The U.S. Food and Drug Administration on Wednesday …
FDA Approves First Gene Therapy in the United States Read More
July 31, 2017 (Medical News Today) A lack of understanding of molecular mechanisms which let cancer cells escape detection from the immune system is a reason why existing chemotherapy and …
Cell mechanism discovery could lead to ‘fundamental’ change in leukemia treatment Read More
July 19, 2017 (Medical News Today) Following an experimental chimeric antigen receptor (CAR) T-cell immunotherapy, researchers presented that 70 percent of patients with the most common adult leukemia had tumor …
CAR T-cell therapy for leukemia leads to remissions in clinical trial Read More
July 1, 2017 (Medical News Today) The cancer drug, rituximab, is not a chemotherapy, but a monoclonal antibody therapy that uses antibodies which stick to specific cells or proteins and …
Human antibody bolsters cancer drug performance Read More
July 3, 2017 (Medical News Today) Overall, the immune system does a remarkable job defending the body from disease-causing agents. When it comes to cancer, however, it falls short. Niroshana …
New insights into why the immune system fails to see cancer Read More
June 20, 2017 (Medical News Today) Immunotherapy drugs continue to only be effective in about 10 to 30 percent of cancer patients with certain tumor types. A clue has been …
Targeting immune cells that help tumors stay hidden could improve immunotherapy Read More
June 12, 2017 (Medical News Today) A nanoparticle has been created by scientists at Johns Hopkins, supporting two unique antibodies that may have the power of “switching off” destructive properties …
“Immunoswitch” particles may be key to more-effective cancer immunotherapy Read More
December 1, 2016 (Blood) “Chimeric antigen receptors (CARs) are fusion proteins that combine antigen-recognition domains and T-cell signaling domains.” T cells harvested from patients’ blood and re-engineered to express CARs …
T Cells Expressing a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor Induce Remissions of Advanced Lymphoma in a First-in-Humans Clinical Trial Read More January 5, 2017 (ScienceDaily.com) Lymphoma, the most common blood cancer, is the result of the uncontrollable multiplication of lymphocytes (immune cells). B-cell lymphomas account for 85% of patients who have …
Immune cell therapy shows promising results for lymphoma patients Read More